Next wave of COVID vaccine developers could yet capture market share, with room for shares to run

Investors will need to sort through uncertainties around COVID-19 booster shots and global vaccine rollout to determine whether a second wave of vaccine developers still have room for their share prices to run once they reach the market, or whether they’re already valued with all of their future opportunities in mind.

A handful of biotechs will be looking for ways to position their vaccines in a changing environment that could offer ways to find a niche beyond the market carved out by the first vaccines to gain authorization...